PANCREATIC ACINAR CELL CARCINOMA
Clinical trials for PANCREATIC ACINAR CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC ACINAR CELL CARCINOMA trials appear
Sign up with your email to follow new studies for PANCREATIC ACINAR CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental vaccine targets Hard-to-Treat pancreatic tumors
Disease control OngoingThis early-phase study tested a special vaccine (PANVAC) given directly into the tumor plus under the skin, along with a drug that boosts immune cells (sargramostim), in 18 people with advanced pancreatic cancer that could not be removed by surgery. The main goal was to find the …
Matched conditions: PANCREATIC ACINAR CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:49 UTC
-
Experimental drug cocktail targets Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a combination of two targeted drugs (vismodegib and erlotinib) with or without standard chemotherapy (gemcitabine) in people with advanced pancreatic cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the safest d…
Matched conditions: PANCREATIC ACINAR CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:48 UTC
-
Immunotherapy duo takes on rare tumors in nationwide trial
Disease control OngoingThis study tests two immunotherapy drugs, nivolumab and ipilimumab, in adults with over 50 types of rare cancers. The goal is to see if this drug combination can shrink tumors or stop them from growing. The trial is no longer enrolling new participants, but results will help guid…
Matched conditions: PANCREATIC ACINAR CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:44 UTC
-
New Three-Drug cocktail targets genetic weakness in tough pancreatic cancer
Disease control OngoingThis study compares a three-drug chemotherapy combination (nab-paclitaxel, gemcitabine, plus cisplatin) against the standard two-drug combination (nab-paclitaxel plus gemcitabine) for people with metastatic pancreatic cancer that has spread to other parts of the body. Only patien…
Matched conditions: PANCREATIC ACINAR CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 22, 2026 14:02 UTC